EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieFall-Kontroll-StudieOpen Access · CC BY-NC-ND 4.0

Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study

Kosuke Ebina, Tomonori Kobayakawa, Yuki Etani, Takaaki Noguchi, Masafumi Kashii, Gensuke Okamura, Yoshio Nagayama, Hideki Tsuboi, Akira Miyama, Makoto Hirao, Yuji Fukuda, Takuya Kurihara und 3 weitere

Bone · 2025

DOI: 10.1016/j.bone.2025.117389 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Bone, 2025. Verfasst von Kosuke Ebina und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; Department of Sports M…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Teriparatide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the impact of prior teriparatide (TPTD) treatment on the effectiveness of romosozumab (ROMO) in postmenopausal osteoporosis. METHODS: In this retrospective, case-controlled, multicenter study, 323 postmenopausal patients were initiated ROMO. Of these, 275 were treatment-naïve, and 48 were switched from TPTD, with uninterrupted ROMO treatment for 12 months. Propensity score matching was applied to ensure clinical comparability, yielding 44 patients in each group. Baseline characteristics included a mean age of 78.0 years, lumbar spine (LS) T-score of -3.6, and total hip (TH) T-score of -2.8. Bone mineral density (BMD) and serum bone turnover markers were evaluated over the 12-month period. RESULTS: The increasing rate in the bone formation marker PINP was significantly greater in the treatment-naïve group compared to the TPTD-switched group throughout the 1-12 month period. Conversely, the reduction in the bone resorption marker TRACP-5b was similar between the groups, indicating a diminished anabolic window in the TPTD-switched group. After 12 months, the TPTD-switched group showed lower BMD gains in the LS (10.3 % vs. 17.3 %; P = 0.002) and TH (3.1 % vs. 7.8 %; P = 0.002) compared to the treatment-naïve group. Multiple regression analysis revealed positive associations between the 12-month percentage BMD increases (LS; β = 0.30; 95 % CI = 0.85-11.61; P = 0.024 / TH; β = 0.32; 95 % CI = 0.51-8.56; P = 0.028) and being treatment-naïve compared to prior TPTD treatment. CONCLUSIONS: Prior TPTD treatment may attenuate the effectiveness of ROMO, potentially due to diminished bone formation activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBone Density Conservation AgentsOsteoporosis, PostmenopausalTeriparatideAgedAged, 80 and overFemaleHumansBiomarkersBone DensityBone RemodelingCase-Control StudiesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Bone formationBone mineral densityPostmenopausal osteoporosisRomosozumabTeriparatide

Substanzen

Antibodies, MonoclonalBiomarkersBone Density Conservation AgentsromosozumabTeriparatide

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2…
  • Kobayakawa Orthopaedic and Rheumatologic Clinic, 1969 Kunou, Fukuroi, Shizuoka 437-0061, Japan.
  • Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
  • Department of Orthopaedic Surgery, NHO Osaka Minami Medical Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka 586-8521, Japan.
  • Nagayama Rheumatology and Orthopaedic Clinic, 4-3-25 Hiokisounishi-machi, Higashi-ku, Sakai 599-8114, Japan.

Zitieren

APA

Ebina, K., Kobayakawa, T., Etani, Y., Noguchi, T., Kashii, M., Okamura, G., Nagayama, Y., Tsuboi, H., Miyama, A., Hirao, M., Fukuda, Y., Kurihara, T., Sugimoto, A., Nakata, K., & Okada, S. (2025). Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study. Bone. https://doi.org/10.1016/j.bone.2025.117389

Vancouver

Ebina K, Kobayakawa T, Etani Y, Noguchi T, Kashii M, Okamura G, et al. Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study. Bone. 2025. doi:10.1016/j.bone.2025.117389

BibTeX
@article{Ebina2025,
  author = {Ebina, Kosuke and Kobayakawa, Tomonori and Etani, Yuki and Noguchi, Takaaki and Kashii, Masafumi and Okamura, Gensuke and Nagayama, Yoshio and Tsuboi, Hideki and Miyama, Akira and Hirao, Makoto and Fukuda, Yuji and Kurihara, Takuya and Sugimoto, Atsushi and Nakata, Ken and Okada, Seiji},
  title = {Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study},
  journal = {Bone},
  year = {2025},
  doi = {10.1016/j.bone.2025.117389}
}
Kostenlos starten →